Loading
NASDAQHealthcareMedical - Devices
Latest quote
$1.8352
−$0.0548 · -2.90%
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Previous close
$1.8352
−$0.0548 · -2.90%
Regular session · ET · Market data may be delayed.
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Day range
Current $1.8352
52-week range
Current $1.8352
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
36
Expensive
Sentiment
53
Mixed
Risk
62
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Day range
Current $1.8352
52-week range
Current $1.8352
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 4.45M USD | 5.31M USD | 5.42M USD | 5.34M USD | 18.87M USD |
| Cost of goods sold | 4.09M USD | 4.81M USD | 4.8M USD | 4.89M USD | 15.89M USD |
| Gross profit | 362K USD | 498K USD | 611K USD | 446K USD | 2.98M USD |
| Research and development | 788K USD | 1.02M USD | 1.49M USD | 1.58M USD | 1.81M USD |
| Selling, general, and administrative | 4.89M USD | 4.61M USD | 5.49M USD | 6.09M USD | 5.7M USD |
| Operating expenses | 5.68M USD | 5.64M USD | 6.98M USD | 7.67M USD | 7.51M USD |
| Interest income | 1.23M USD | 165K USD | 431K USD | 133K USD | 27K USD |
| Depreciation and amortization | 421K USD | 400K USD | 374K USD | 351K USD | 594.82K USD |
| Operating income | −5.32M USD | −5.14M USD | −6.37M USD | −7.22M USD | −4.53M USD |
| Net income | −3.78M USD | −4.97M USD | −5.98M USD | −7.14M USD | −4.53M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
